Women-focused health startup Maven valued at $1.7 bln in funding round
Maven raises $125 mln in funding round
Funding round led by investment firm StepStone
Maven's total funding climbs over $425 mln
Adds valuation in headline and paragraph 1, CEO comments in paragraphs 5-6
By Arasu Kannagi Basil and Niket Nishant
Oct 8 (Reuters) -Women-focused healthcare firm Maven Clinic was valued at $1.7 billion after it raised $125 million in its latest funding round led by private markets investment firm StepStone Group STEP.O, it said on Tuesday.
Maven's existing investors General Catalyst, Sequoia, Oak HC/FT, Icon Ventures, Dragoneer Investment Group and Lux Capital also participated in the round, the company said.
Startups focused on women's health challenges are steadily gaining traction with venture capital investors, driven by a growing recognition of the need for targeted healthcare solutions.
A report from the World Economic Forum and the McKinsey Health Institute in January found women spend 25% more of their lives in debilitating health compared with men.
"Early on, people didn't understand the size of the sector and how powerful it is. It was clearly one of the great missed opportunities over the last few decades in health care innovation," said Kate Ryder, founder and CEO of Maven.
"Women and family health is not just a huge area of health care that's been undersupported and under-funded, it actually is the central part of health care."
Founded in 2014, Maven partners with employers and health plans to provide clinical support through its platform on preconception, family building, pregnancy, parenting and menopause.
The New York-based firm caters to more than 2,000 customers in 175 countries. Telecom operator AT&T T.N, Wall Street giant Morgan Stanley MS.N and French cosmetics giant L'Oreal OREP.PA use its services to support their employees' health needs.
The latest financing round brings Maven's total funding to more than $425 million, the company said. Maven had last raised $90 million in a Series E funding round in 2022 led by General Catalyst.
The company will use the proceeds to further invest in Maven Managed Benefit, its fertility benefits administration platform. It will also bolster its offerings across both fully insured and Medicaid populations.
Reporting by Arasu Kannagi Basil and Niket Nishant in Bengaluru and Krystal Hu in New York; Editing by Krishna Chandra Eluri
Aset Berkaitan
Berita Terkini
Penafian: Entiti XM Group menyediakan perkhidmatan pelaksanaan sahaja dan akses ke Kemudahan Dagangan Atas Talian, yang membolehkan sesorang melihat dan/atau menggunakan kandungan yang ada di dalam atau melalui laman web, tidak bertujuan untuk mengubah atau memperluas, juga tidak mengubah atau mengembangkannya. Akses dan penggunaan tersebut tertakluk kepada: (i) Terma dan Syarat; (ii) Amaran Risiko; dan Penafian Penuh. Oleh itu, kandungan sedemikian disediakan tidak lebih dari sekadar maklumat umum. Terutamanya, perlu diketahui bahawa kandungan Kemudahan Dagangan Atas Talian bukan permintaan, atau tawaran untuk melakukan transaksi dalam pasaran kewangan. Berdagang dalam mana-mana pasaran kewangan melibatkan tahap risiko yang besar terhadap modal anda.
Semua bahan yang diterbitkan di Kemudahan Dagangan Atas Talian kami bertujuan hanya untuk tujuan pendidikan/maklumat dan tidak mengandungi – dan tidak boleh dianggap mengandungi nasihat kewangan, cukai pelaburan atau dagangan dan cadangan, atau rekod harga dagangan kami, atau tawaran, atau permintaan untuk suatu transaksi dalam sebarang instrumen kewangan atau promosi kewangan yang tidak diminta kepada anda.
Sebarang kandungan pihak ketiga serta kandungan yang disediakan oleh XM, seperti pendapat, berita, penyelidikan, analisis, harga, maklumat lain atau pautan ke laman web pihak ketiga yang terdapat dalam laman web ini disediakan berdasarkan "seadanya" sebagai ulasan pasaran umum dan bukanlah nasihat pelaburan. Sesuai dengan apa-apa kandungan yang ditafsir sebagai penyelidikan pelaburan, anda mestilah ambil perhatian dan menerima bahawa kandungan tersebut tidak bertujuan dan tidak sediakan berdasarkan keperluan undang-undang yang direka untuk mempromosikan penyelidikan pelaburan bebas dan oleh itu, ia dianggap sebagai komunikasi pemasaran di bawah peraturan dan undang-undang yang berkaitan. SIla pastikan bahawa anda telah membaca dan memahami Notifikasi mengenai Penyelidikan Pelaburan Bukan Bebas dan Amaran Risiko mengenai maklumat di atas yang boleh diakses di sini.
